Development of a hepatitis C virus vaccine

Clinics in Liver Disease

Volumn 7, Issue 1, 2003, Pages 243-259

  Inchauspé, Genevieve ^a   Feinstone, Stephen ^b  

^a UNIVERSITÉ DE LYON   (France)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HEPATITIS VACCINE; LIVE VACCINE; PEPTIDE DERIVATIVE;

ANTIGENICITY; CLINICAL TRIAL; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION PREVENTION; INFECTION RATE; MICROBIAL DIVERSITY; NONHUMAN; PERSISTENT VIRUS INFECTION; REVIEW; TREATMENT OUTCOME; VACCINATION; VIRUS TRANSMISSION;

ANIMALS; HEPACIVIRUS; HEPATITIS C; HUMANS; MICE; PAN TROGLODYTES; VACCINATION; VACCINES, ATTENUATED; VACCINES, COMBINED; VACCINES, DNA; VACCINES, SUBUNIT; VIRAL HEPATITIS VACCINES;

EID: 0037300153     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(02)00067-3     Document Type: Review

References (63)

1. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 1994;91:1294-8.
2. Alter MJ. The detection, transmission and outcome of hepatitis C virus infection. Infect Agents Dis 1993;2:155-66.
3. Bruna-Romero O, Lasarte JJ, Wilkinson G, et al. Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology 1997;25:470-7.
4. Wentworth PA, Sette A, Celis E, et al. Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. Int Immunol 1995;8:651-9.
5. Prince AM, Brotman T, Huima D, et al. Immunity in hepatitis C virus infection. J Infect Dis 1992;165:438-43.
6. Blight K, Kolykhalov AA, Rice CM. Efficient replication of HCV RNA replication in cell culture. Science 2000;290:1972-4.
7. Pawlotsky JM, Pellerin M, Bouvier M, et al. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J Med Virol 1998;54:256-64.
8. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999:31:54-60.
9. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alpha-2b in combination with ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomized trial. Lancet 2001;358:958-65.
10. Jessner W, Gschwantler M, Steindl-Munda P, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001;358:1241-2.
11. Cerny A, McHutchinson JG, Pasquinelli C, et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA-A2 binding motif. J Clin Invest 1995;95:521-30.
12. Cucchiarini M, Kammer AR, Grabscheid B, et al. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol 2000;203:111-23.
13. Thimme R, Oldach D, Chang K-M, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-406.
14. Vertuani S, Bazzaro M, Gualandi G, et al. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur J Immunol 2002;32:144-54.
15. Diepolder HM, Gerlach JT, Zachoval R, et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1995;71:6011-9.
16. Koziel M, Dudley D, Afdhal N, et al. HLA class-restricted cytotoxic T lymphocytes specific for hepatitis C virus. J Clin Invest 1995;95:521-30.
17. Rehermann B, Chang KM, McHutchinson J, et al. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C infection. J Clin Invest 1996;98:1432-40.
18. Lechmann M, Murata K, Satoi J, et al. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune response in mice. Hepatology 2001;34:417-23.
19. Lechner F, Gruener NH, Urbani S, et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 2000;30:2479-87.
20. Erickson AL, Kimura Y, Igarashi S, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001;15:883-95.
21. Bain C, Fatmi A, Zoulim F, et al. Chronic infection by hepatitis C virus is associated with impairment of allostimulatory function of monocyte-derived dendritic cells and stringent selection of viral variants. Gastroenterology 2001;120:512-24.
22. Kanto T, Hayashi N, Takehara T, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 1999;162:5584-91.
23. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after Ab-mediated in vitro neutralization. Proc Natl Acad Sci U S A 1994;91:7792-6.
24. Shimizu YK, Feinstone SM, Kohara M, et al. Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology 1996;23:205-9.
25. Yu MW, Shen LM, Major ME, Feinstone SM, et al. Protective antibodies in immune globulins prepared from anti-HCV positive plasma units: update of a chimpanzee study. Proceeding of the 10th International Symposium on Viral Hepatitis and Liver Disease, in press.
26. Cooper S, Erickson AL, Adams EJ, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10:439-49.
27. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6:578-82.
28. Battegay M, Fikes J, Di Bisceglie AM, et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995;69:2462-70.
29. Hiranuma K, Tamaki S, Nishimura Y, et al. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. J Gen Virol 1999;80:187-93.
30. Shirai M, Arici T, Nishioka M, et al. CTL response of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J Immunol 1995;154:2733-42.
31. Sarobe P, Pendleton CD, Akatsuka T, et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Invest 1998;102:1239-48.
32. Lopez-Diaz de Cerio A, Casares N, Lasarte JJ, et al. Th1 but not Th0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides. Int Immunol 1999;11:2025-33.
33. Prezzi C, Nuzzo M, Meola A, et al. Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients. J Imunol 1996;156:4504-13.
34. Puntoriero G, Meola A, Lahm A, et al. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J 1998;17:3521-33.
35. Heile JM, Fong YL, Rosa D, et al. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA6based vaccine candidates. J Virol 2000;74:6885-92.
36. Rosa D, Campagnoli S, Moretto C, et al. A quantitative test to estimate neutralizing antibodies to hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A 1996;93:1759-63.
37. Baumert TF, Vergalla J, Satoi J, et al. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology 1999;117:1397-407.
38. Moriya O, Matsui M, Osorio M, et al. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein. Vaccine 2002;20:789-96.
39. Polakos NK, Drane D, Cox J, et al. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by nonclassical ISCOM vaccine. J Immunol 2001;166:3589-98.
40. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
41. Brinster C, Inchauspé G. DNA vaccines for hepatitis C virus. Intervirology 2001a;144:143-53.
42. Geissler M, Gesien A, Tokushige K, et al. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997;158:1231-7.
43. Renard N, Boucreux D, Lemonnier F, et al. HLA-A2.1 transgenic mouse model: potential utility for development of an HCV vaccine. J Hepatol 2000;32:362-4.
44. Tokushige K, Wakita T, Pachuk G, et al. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatology 1996;24:14-20.
45. Vidalin O, Fournillier A, Renard N, et al. Use of conventional or replicating nucleic acid-based vaccines and recombinant semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens. Virology 2000;276:259-70.
46. Brinster C, Chen M, Boucreux D, et al. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant semliki forest virus particles. J Gen Virol 2002;83:369-81.
47. Nakano I, Maertens G, Major ME, et al. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol 1997;71:7101-9.
48. Saito T, Sherman GJ, Kurokohchi K, et al. Plasmid DNA-based immunization for hepatitis C virus structural proteins: immune responses in mice. Gastroenterology 1997;112:1321-30.
49. Forns X, Emerson SU, Tobin GJ, et al. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine 1999;17:1992-2002.
50. Lee SW, Cho JH, Sung YC. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol 1998;72:8430-6.
51. Fournillier A, Karaiyannis P, Vidalin O, et al. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol 1999;73:7497-504.
52. Sodora DL, Cohen GH, Muggeridge MI, et al. Absence of asparagines-linked oligosaccharides from glycoprotein D of herpes simplex virus type 1 results in a structurally altered but biologically active protein. J Virol 1991;65:4424-31.
53. Fournillier A, Wychowsky C, Boucreux D, et al. Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of the N-glycosylation sites. J Virol 2001;75:12088-97.
54. Satoi J, Murata K, Lechmann M, et al. Genetic immunization of wild type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins. J Virol 2001;75:12121-7.
55. Encke J, Zu PJ, Geissler M, et al. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 1998;161:4917-23.
56. Cho JH, Lee SW, Sung YC. Enhanced cellular immunity tohepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization. Vaccine 1999;17:1136-44.
57. Makimura M, Miyake S, Akino N, et al. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine 1996;14:28-34.
58. Wedemeyer H, Gagneten S, Davis A, et al. Oral immunization with HCV-NS3 transformed Salmonella: induction of HCV-specific CTL in a trangenic mouse model. Gastroenterology 2001;121:1158-66.
59. Pancholi P, Liu Q, Tricoche N, et al. DNA prime-Canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. J Infect Dis 2000;182:18-27.
60. Vidalin O, Tanaka E, Spengler U, et al. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. DNA Cell Biol 1999;18:611-21.
61. Himoudi N, Abraham JD, Fournillier A, et al. Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in Hepatitic C virus natural infection. J Virol 2002;76(24):12735-46.
62. Verschoor E, Drexhage J, Verstrepen B, et al. Vaccination of chimpanzees with a mulicomponent DNA-protein prime-boost regimen provides an enhanced recovery following heterologous HCV challenge. In: Programs and abstracts of the 8th International Symposium on Hepatitis C Virus and Related Viruses. Paris; 2001. p. 78.
63. Leroux-Roels G, Depla E, Hulstaert F, et al. A candidate therapeutic vaccine for chronic hepatitis C infection based on envelope 1 protein: tolerability and immunogenicity in healthy adult volunteers. In: Programs and abstracts of the 8th International Symposium on Hepatitis C Virus and Related Viruses. Paris; 2001. p. 85.